4,8-Dihydroxy-3,9-dimethyl-6-methylidene-3,3a,4,5,6a,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-2-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4,8-Dihydroxy-3,9-dimethyl-6-methylidene-3,3a,4,5,6a,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-2-one
• 化学式: C₁₅H₂₂O₄
• 分子量: 266.33
• InChiKey: LWHRXFOPIDTJSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
  申请人：InterMed Discovery GmbH

  公开号：EP2345646A1

  公开（公告）日：2011-07-20

  A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic - including prophylactic - treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for decreasing blood cholesterol; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

  式 I 的化合物、 其中符号如其余说明书中所定义，或两种或两种以上式 I 化合物的混合物，作为活性成分用于温血动物的治疗（包括预防性治疗），以调节体重（优选）和/或减脂（优选）和/或控制肥胖和/或降低血液中的胆固醇；式 I 的化合物可以游离形式、药学上和/或营养学上可接受的盐的形式、同分异构体的形式、酯的形式和/或溶解物的形式以及相关的发明实施方案的形式存在。
• USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS
  申请人：Neem Biotech Ltd.

  公开号：EP3260449A1

  公开（公告）日：2017-12-27

  A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic - including prophylactic - treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments.

  式 I 的化合物、 其中符号如其余说明书中所定义，或两种或两种以上式 I 化合物的混合物，作为活性成分用于温血动物的治疗--包括预防--调节体重（优选）和/或减脂（优选）和/或控制肥胖和/或改善总胆固醇 HDL/LDL 比率；其中式 I 的化合物可以游离形式、药学上和/或营养学上可接受的盐的形式、同分异构体的形式、酯的形式和/或溶解物的形式以及相关的发明实施方案的形式存在。
• Tricyclic sesquiterpene lactones for used in the treatment of obesity and related diseases and non-therapeutic treatable conditions
  申请人：Neem Biotech Ltd.

  公开号：EP2523946B1

  公开（公告）日：2017-09-20
• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16
• Chemosensory Receptor Ligand-Based Therapies
  申请人：BARON Alain D.

  公开号：US20120177730A1

  公开（公告）日：2012-07-12

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.